Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Jefferies cuts targets for miners, but still sees upside

(Sharecast News) - Jefferies has trimmed its targets for a host of blue chip mining stocks after calculating the impact that Donald Trump's sweeping trade tariffs would have on export demand and commodity prices. Nevertheless, the broker said that, while miners are likely to experience a "period of weakening demand" due to additional export levies, stocks in the sector are now at "attractive levels for those who can ride out near-term volatility".

Jefferies has cut Anglo American's target price from 3,000p to 2,700p, cut Glencore from 430p to 380p and Rio Tinto from 6,000p to 5,700p - though all three stocks are still rated a 'buy'.

BHP, which has had its target price lowered from 2,150p to 1,800p, is rated a 'hold'.

In the near term, Jefferies predicts that US buyers who have recently accumulated excess inventory of metals will "step out of the market and de-stock" as a result of the tariffs lifting domestic prices.

"This air pocket risk is greatest in copper, aluminum and steel, in our view. More broadly, there is also risk of a sharp slowdown in global growth, which could lead to significantly lower commodity prices. However, this risk appears to be at least partially (but not entirely) reflected in the equities already as valuations have materially de-rated," the broker said.

The most significant cuts Jefferies has made were to seaborne coal price forecasts, while gold estimates have been raised as inflationary fiscal, monetary and trade policies and greater geopolitical risk support precious metal prices.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.